PRELUDE Registry Presented at EBCC 2026

 

We are pleased to share that the PRELUDE registry was presented at the European Breast Cancer Conference (EBCC) 2026 in Barcelona, Spain.

Presented by Dr. Georgios Metaxas (Elena Venizelou General Hospital, Athens, Greece), the study was featured in the Precision Medicine session (Poster 333).

PRELUDE (Prospective, Multicenter REgistry to Observe the Treatment Patterns, ClinicaL OUtcomes, and Decision-Making in Patients with Early Breast Cancer Eligible for EndoPredict Testing) is a prospective, multicenter, investigator-initiated registry designed to generate robust real-world evidence in patients with ER-positive, HER2-negative early breast cancer.

Luminal breast cancer is a biologically heterogeneous disease requiring individualized treatment strategies. The EndoPredict test enables refined risk stratification, supporting more precise identification of patients at low or high risk of recurrence and guiding decisions on adjuvant chemotherapy.

By collecting real-world data across diverse patient populations, PRELUDE provides valuable insights beyond controlled clinical trials. The registry evaluates how genomic profiling aligns with clinicopathological parameters and influences treatment decisions in routine clinical practice.

The study plans to enroll up to 2,000 patients over a 3-year period, with follow-up of up to 10 years.

Key clinical endpoints include:

• Distant relapse-free survival (DRFS) at 5 and 10 years
• Overall survival (OS) at 5 and 10 years
• Distant relapse-free interval (DRFI)
• Impact of EndoPredict on adjuvant chemotherapy decision-making

The study also explores aspects such as concordance between genomic and clinical risk stratification, as well as real-world treatment patterns and outcomes.

As of February 2026, 281 patients have been enrolled across 13 active sites in Greece, with further expansion to additional national and international centers underway.

PRELUDE represents an important contribution to strengthening the evidence base for EndoPredict in real-world settings and supports the advancement of personalized treatment strategies in early breast cancer.

Access the full poster here

Interested in participating in the PRELUDE registry or learning more?
Please contact us at info-int@eurobio-scientific.de